Base de dados : MEDLINE
Pesquisa : E02 [Categoria DeCS]
Referências encontradas : 5170 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 517 ir para página                         

  1 / 5170 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28747306
[Au] Autor:Moreau P
[Ad] Endereço:Department of Hematology, University Hospital and INSERM Unité Mixte de Recherche 892, Centre National de la Recherche Scientifique Unité Mixte de Recherche 6299, University of Nantes, Nantes, France.
[Ti] Título:How I treat myeloma with new agents.
[So] Source:Blood;130(13):1507-1513, 2017 09 28.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:At present, multiple classes of agents with distinct mechanisms of action are available for the treatment of patients with multiple myeloma (MM), including alkylators, steroids, immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), histone deacetylase inhibitors (DACIs), and monoclonal antibodies (mAbs). Over the last 5 years, several new agents, such as the third-generation IMiD pomalidomide, the second-generation PIs carfilzomib and ixazomib, the DACI panobinostat, and 2 mAbs, elotuzumab and daratumumab, have been approved, incorporated into clinical guidelines, and have transformed our approach to the treatment of patients. These agents may be part of doublet or triplet combinations, or incorporated into intensive strategies with autologous stem cell transplantation. In this review, I discuss the different treatment options available today for the treatment of MM in frontline and relapse settings.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Mieloma Múltiplo/tratamento farmacológico
Terapêutica/tendências
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180113
[Lr] Data última revisão:
180113
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2017-05-743203


  2 / 5170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29058855
[Au] Autor:McGary R; Franc J; Chui S; Kim CS; Boehm TK
[Ti] Título:Crown Lengthening Needs and Outcomes in Adults Attending a Predoctoral Clinic.
[So] Source:J Calif Dent Assoc;45(2):73-80, 2017 02.
[Is] ISSN:1043-2256
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this retrospective study of 5,536 patients admitted over four years at a predoctoral dental clinic for comprehensive care, general dentists identified crown lengthening needs in 584 patients and 760 teeth. Only 51 patients and 68 teeth actually received crown lengthening procedures. For the other cases, patients discontinued treatment or chose extraction or restoration without crown lengthening procedures. Teeth that received crown lengthening procedures were most likely restored and functioning for at least one year.
[Mh] Termos MeSH primário: Aumento da Coroa Clínica
Clínicas Odontológicas
[Mh] Termos MeSH secundário: Adulto
Educação em Odontologia
Feminino
Odontologia Geral
Necessidades e Demandas de Serviços de Saúde
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
Terapêutica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:171024
[St] Status:MEDLINE


  3 / 5170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28873411
[Au] Autor:Mahmood E; Knio ZO; Mahmood F; Amir R; Shahul S; Mahmood B; Baribeau Y; Mueller A; Matyal R
[Ad] Endereço:Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.
[Ti] Título:Preoperative asymptomatic leukocytosis and postoperative outcome in cardiac surgery patients.
[So] Source:PLoS One;12(9):e0182118, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Despite showing a prognostic value in general surgical patients, preoperative asymptomatic elevated white blood cell (WBC) count is not considered a risk factor for cardiac surgery. Whereas there is sporadic evidence of its value as a preoperative risk marker, it has not been looked at methodically as a specific index of outcome during cardiac surgery. Using a national database we sought to determine the relationship between preoperative WBC count and postoperative outcome in cardiac surgical patients. METHODS: Cardiac surgeries were extracted from the 2007-2013 American College of Surgeons National Surgical Quality Improvement Program database. Leukocytosis was defined by a preoperative WBC count greater than 11,000 cells/µL. A univariate analysis compared the incidence of adverse outcomes for patients with and without leukocytosis. A multivariate logistic regression model was constructed in order to test whether leukocytosis was an independent predictor of morbidity and mortality. RESULTS: Out of a total of 10,979 cardiac surgery patients 863 (7.8%) had preoperative leukocytosis. On univariate analysis, patients with leukocytosis experienced greater incidences of 30-day mortality, wound complications, and medical complications. Wound complications included surgical site infection as well as wound dehiscence. The medical complications included all other non-surgical causes of increased morbidity and infection leading to urinary tract infection, pneumonia, ventilator dependence, sepsis and septic shock. After stepwise model adjustment, leukocytosis was a strong predictor of medical complications (OR 1.22, 95% CI: 1.09-1.36, p = 0.002) with c-statistic of 0.667. However, after stepwise model adjustment leukocytosis was not a significant predictor of 30-day mortality and wound complications. CONCLUSION: Preoperative leukocytosis is associated with adverse postoperative outcome after cardiac surgery and is an independent predictor of infection-related postoperative complications.
[Mh] Termos MeSH primário: Procedimentos Cirúrgicos Cardíacos/efeitos adversos
Leucocitose/complicações
Cuidados Pós-Operatórios
Cuidados Pré-Operatórios
[Mh] Termos MeSH secundário: Seres Humanos
Contagem de Leucócitos
Leucocitose/sangue
Modelos Logísticos
Complicações Pós-Operatórias/etiologia
Terapêutica
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182118


  4 / 5170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28817373
[Au] Autor:Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
[Ad] Endereço:Maria E. Cabanillas and Komal Shah, The University of Texas MD Anderson Cancer Center, Houston, TX; Jonas A. de Souza, University of Chicago Medical Center, Chicago, IL; Susan Geyer, University of South Florida, Tampa; Michael E. Menefee, Mayo Clinic Jacksonville, Jacksonville, FL; Lori J. Wirth, Ma
[Ti] Título:Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
[So] Source:J Clin Oncol;35(29):3315-3321, 2017 Oct 10.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose Sorafenib and lenvatinib are oral multikinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR) and approved for radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). However, there are no approved second- or third-line therapies. MET is implicated in resistance to VEGFR inhibitors. Cabozantinib is an oral multikinase inhibitor targeting MET in addition to VEGFR and is approved for medullary thyroid cancer. In a phase I study of cabozantinib, five of eight patients with DTC previously treated with a VEGFR-targeted therapy had an objective response to cabozantinib. Patients and Methods Patients with RAI-refractory disease with Response Evaluation Criteria in Solid Tumor (RECIST) measurable disease and evidence of progression on prior VEGFR-targeted therapy were enrolled in this single-arm phase II study. The cabozantinib starting dose was 60 mg/day orally but could be escalated to 80 mg if the patient did not experience a response. Patients underwent tumor assessment according to RECIST v1.1 every 8 weeks. In this study, if at least five of 25 response-evaluable patients had an objective response, cabozantinib would be considered a promising agent in this patient population. Results Twenty-five patients were enrolled. The median age was 64 years, and 64% of patients were men. Twenty-one patients had received only one prior VEGFR-targeted therapy (sorafenib, pazopanib, or cediranib), and four patients had received two such therapies. The most common treatment-related adverse events were fatigue, weight loss, diarrhea, palmar-plantar erythrodysesthesia, and hypertension. One drug-related death was noted. Of the 25 patients, 10 (40%) had a partial response, 13 (52%) had stable disease, and two (8%) had nonevaluable disease. The median progression-free survival and overall survival were 12.7 months and 34.7 months, respectively. Conclusion Cabozantinib demonstrated clinically significant, durable objective response activity in patients with RAI-refractory DTC who experienced disease progression while taking prior VEGFR-targeted therapy.
[Mh] Termos MeSH primário: Anilidas/uso terapêutico
Diferenciação Celular
Resistência a Medicamentos Antineoplásicos
Inibidores de Proteínas Quinases/uso terapêutico
Proteínas Proto-Oncogênicas c-met/antagonistas & inibidores
Piridinas/uso terapêutico
Receptores de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores
Terapia de Salvação
Neoplasias da Glândula Tireoide/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Anilidas/efeitos adversos
Progressão da Doença
Intervalo Livre de Doença
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Terapia de Alvo Molecular
Estudos Prospectivos
Inibidores de Proteínas Quinases/efeitos adversos
Proteínas Proto-Oncogênicas c-met/metabolismo
Piridinas/efeitos adversos
Receptores de Fatores de Crescimento do Endotélio Vascular/metabolismo
Transdução de Sinais/efeitos dos fármacos
Terapêutica
Neoplasias da Glândula Tireoide/enzimologia
Neoplasias da Glândula Tireoide/mortalidade
Neoplasias da Glândula Tireoide/patologia
Fatores de Tempo
Estados Unidos
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Anilides); 0 (Protein Kinase Inhibitors); 0 (Pyridines); 1C39JW444G (cabozantinib); EC 2.7.10.1 (MET protein, human); EC 2.7.10.1 (Proto-Oncogene Proteins c-met); EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2017.73.0226


  5 / 5170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28758680
[Au] Autor:Moore GF; Evans RE; Hawkins J; Littlecott HJ; Turley R
[Ti] Título:All interventions are complex, but some are more complex than others: using iCAT_SR to assess complexity.
[So] Source:Cochrane Database Syst Rev;7:ED000122, 2017 07 11.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Literatura de Revisão como Assunto
Terminologia como Assunto
Terapêutica/classificação
[Mh] Termos MeSH secundário: Terapêutica/métodos
[Pt] Tipo de publicação:EDITORIAL
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170801
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.ED000122


  6 / 5170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28679092
[Au] Autor:Woodcock J; LaVange LM
[Ad] Endereço:From the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
[Ti] Título:Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.
[So] Source:N Engl J Med;377(1):62-70, 2017 07 06.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Protocolos Clínicos
Ensaios Clínicos como Assunto/organização & administração
Terapêutica
[Mh] Termos MeSH secundário: Doença
Seres Humanos
Projetos de Pesquisa
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170706
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMra1510062


  7 / 5170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28674332
[Au] Autor:Hatakeyama H
[Ad] Endereço:Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University.
[Ti] Título:Recent Advances in Endogenous and Exogenous Stimuli-Responsive Nanocarriers for Drug Delivery and Therapeutics.
[So] Source:Chem Pharm Bull (Tokyo);65(7):612-617, 2017.
[Is] ISSN:1347-5223
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Significant progress has been achieved in the development of stimuli-responsive nanocarriers for drug delivery, diagnosis, and therapy. Various types of triggers are utilized in the development of nanocarrier delivery. Endogenous factors such as changes in pH, redox, gradient, and enzyme concentration which are linked to disease progression have been utilized for controlling biodistribution and releasing drugs from nanocarriers, as well as increasing subsequent pharmacological activity at the disease site. Nanocarriers which respond to artificially-induced exogenous factors (such as temperature, light, magnetic field, and ultrasound) have also been developed. This review aims to discuss recent advances in the design of stimuli-responsive nanocarriers which appear to have a promising future in medicine.
[Mh] Termos MeSH primário: Portadores de Fármacos
Nanopartículas
Terapêutica
[Mh] Termos MeSH secundário: Febre
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Drug Carriers)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE
[do] DOI:10.1248/cpb.c17-00068


  8 / 5170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28630973
[Au] Autor:Boutron I; Altman DG; Moher D; Schulz KF; Ravaud P; CONSORT NPT Group
[Ad] Endereço:From Paris Descartes University, INSERM UMR1153, and Assistance Publique des Hôpitaux de Paris, Paris, France; University of Oxford, Oxford, United Kingdom; Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada; FHI 360, Durham, North Carolina; University of North Caro
[Ti] Título:CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts.
[So] Source:Ann Intern Med;167(1):40-47, 2017 Jul 04.
[Is] ISSN:1539-3704
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Incomplete and inadequate reporting is an avoidable waste that reduces the usefulness of research. The CONSORT (Consolidated Standards of Reporting Trials) Statement is an evidence-based reporting guideline that aims to improve research transparency and reduce waste. In 2008, the CONSORT Group developed an extension to the original statement that addressed methodological issues specific to trials of nonpharmacologic treatments (NPTs), such as surgery, rehabilitation, or psychotherapy. This article describes an update of that extension and presents an extension for reporting abstracts of NPT trials. To develop these materials, the authors reviewed pertinent literature published up to July 2016; surveyed authors of NPT trials; and conducted a consensus meeting with editors, trialists, and methodologists. Changes to the CONSORT Statement extension for NPT trials include wording modifications to improve readers' understanding and the addition of 3 new items. These items address whether and how adherence of participants to interventions is assessed or enhanced, description of attempts to limit bias if blinding is not possible, and specification of the delay between randomization and initiation of the intervention. The CONSORT extension for abstracts of NPT trials includes 2 new items that were not specified in the original CONSORT Statement for abstracts. The first addresses reporting of eligibility criteria for centers where the intervention is performed and for care providers. The second addresses reporting of important changes to the intervention versus what was planned. Both the updated CONSORT extension for NPT trials and the CONSORT extension for NPT trial abstracts should help authors, editors, and peer reviewers improve the transparency of NPT trial reports.
[Mh] Termos MeSH primário: Editoração/normas
Ensaios Clínicos Controlados Aleatórios como Assunto/normas
[Mh] Termos MeSH secundário: Controle de Qualidade
Projetos de Pesquisa/normas
Terapêutica/normas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.7326/M17-0046


  9 / 5170 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28586891
[Au] Autor:Taran S; Detsky AS
[Ad] Endereço:Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
[Ti] Título:It's a Beautiful Thing.
[So] Source:JAMA;317(21):2165-2166, 2017 06 06.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Estética
Medicina
Terapêutica
[Mh] Termos MeSH secundário: Seres Humanos
Matemática
Cirurgia Plástica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170607
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.3102


  10 / 5170 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28541344
[Au] Autor:Medina-Sánchez M; Schmidt OG
[Ad] Endereço:Micro and Nano-biomedical Engineering Group at the Leibniz IFW in Dresden, Germany.
[Ti] Título:Medical microbots need better imaging and control.
[So] Source:Nature;545(7655):406-408, 2017 05 24.
[Is] ISSN:1476-4687
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Materiais Biocompatíveis/análise
Materiais Biocompatíveis/normas
Equipamentos para Diagnóstico
Microquímica/instrumentação
Robótica/instrumentação
Terapêutica/instrumentação
[Mh] Termos MeSH secundário: Ensaios Clínicos como Assunto
Seres Humanos
Movimento (Física)
Nanomedicina/instrumentação
[Pt] Tipo de publicação:JOURNAL ARTICLE; VIDEO-AUDIO MEDIA
[Nm] Nome de substância:
0 (Biocompatible Materials)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE
[do] DOI:10.1038/545406a



página 1 de 517 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde